"Signal-on" electrochemical detection of BACE1 for early detection of Alzheimer's disease

被引:2
|
作者
Chang, Zhu [1 ]
Zhu, Bicheng [3 ]
Liu, Jinjin [1 ]
Dong, Hui [1 ]
Hao, Yuanqiang [2 ]
Zhou, Yanli [1 ]
Travas-Sejdic, Jadranka [3 ,4 ]
Xu, Maotian [1 ]
机构
[1] Shangqiu Normal Univ, Coll Chem & Chem Engn, Henan Key Lab Biomol Recognit & Sensing, Henan Joint Int Res Lab Chemo Biosensing & Early D, Shangqiu 476000, Henan, Peoples R China
[2] Hunan Univ Sci & Technol, Sch Chem & Chem Engn, Key Lab Theoret Organ Chem & Funct Mol, Minist Educ, Xiangtan 411201, Peoples R China
[3] Univ Auckland, Ctr Innovat Mat & Hlth, Sch Chem Sci, Auckland 92019, New Zealand
[4] Victoria Univ Wellington, MacDiarmid Inst Adv Mat & Nanotechnol, POB 600, Wellington, New Zealand
来源
CELL REPORTS PHYSICAL SCIENCE | 2024年 / 5卷 / 08期
基金
中国国家自然科学基金;
关键词
ENZYME; 1; BACE1; INHIBITORS; FERROCENE; BIOSENSOR; TRYPSIN; DESIGN;
D O I
10.1016/j.xcrp.2023.101632
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
beta-Secretase, the beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1), is a key hydrolytic enzyme in the pathway of beta-amyloid (A beta) production in the brain of a patient with Alzheimer's disease (AD). BACE1 is considered a promising biomarker for the early detection of AD. A ferrocene probe (Fc-Probe) is synthesized, where the aldehyde group on the probe can specifically recognize the N terminus of the APP peptide fragment. The sensor's design involves gold nanoparticles (AuNPs) on a glassy carbon electrode (GCE) surface, which allows for the binding of the APP peptide fragment. When BACE1 cleaves the acetylated APP peptide, the N terminus is exposed and triggers an electrochemical signal from the Fc-Probe. The developed sensor can detect BACE1 in a range of 0.02 to 50 U/mL, with a detection limit of 8.0 mU/mL. Such a BACE1 sensor provides a simple, sensitive, and low-cost detection methodology, enabling the "signal-on" detection of BACE1 activity.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease
    Shah, Hirak
    Patel, Ashish
    Parikh, Vruti
    Nagani, Afzal
    Bhimani, Bhargav
    Shah, Umang
    Bambharoliya, Tushar
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (03) : 184 - 194
  • [42] Autoantibodies to BACE1 promote Aβ accumulation and neurodegeneration in Alzheimer's disease
    Wang, Ye-Ran
    Zeng, Xiao-Qin
    Wang, Jun
    Fowler, Christopher J.
    Li, Qiao-Xin
    Bu, Xian-Le
    Doecke, James
    Maruff, Paul
    Martins, Ralph N.
    Rowe, Christopher C.
    Masters, Colin L.
    Wang, Yan-Jiang
    Liu, Yu-Hui
    ACTA NEUROPATHOLOGICA, 2024, 148 (01)
  • [43] Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease
    Thaisrivongs, David K.
    Miller, Steven P.
    Molinaro, Carmela
    Chen, Qinghao
    Song, Zhiguo J.
    Tan, Lushi
    Chen, Lu
    Chen, Wenyong
    Lekhal, Azzeddine
    Pulicare, Sarah K.
    Xu, Yanke
    ORGANIC LETTERS, 2016, 18 (22) : 5780 - 5783
  • [44] The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease
    Robert Vassar
    Patty C Kandalepas
    Alzheimer's Research & Therapy, 3
  • [45] Fueling the Alzheimer's BACE1 race with genetic insights and cyclopropyloxazine BACE1 inhibitors
    Minatti, Ana
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [46] Changes in BACE1 and BACE2 Expresssion in Alzheimer's Disease and Down Syndrome
    Laux, Ashley
    Webb, Robin
    Holler, Chris
    Dowling, Amy
    Beckett, Tina
    Murphy, M. Paul
    FASEB JOURNAL, 2010, 24
  • [47] BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
    Sjolander, Annica
    Zetterberg, Henrik
    Andreasson, Ulf
    Minthon, Lennart
    Blennow, Kaj
    MOLECULAR NEURODEGENERATION, 2010, 5
  • [48] Splice variants of the Alzheimer's disease beta-secretase, BACE1
    Holsinger, R. M. Damian
    Goense, Nelleke
    Bohorquez, John
    Strappe, Padraig
    NEUROGENETICS, 2013, 14 (01) : 1 - 9
  • [49] Glycosaminoglycan-induced activation of the β-secretase (BACE1) of Alzheimer's disease
    Klaver, David W.
    Wilce, Matthew C. J.
    Gasperini, Robert
    Freeman, Craig
    Juliano, John Paul
    Parish, Christopher
    Foa, Lisa
    Aguilar, Marie-Isabel
    Small, David H.
    JOURNAL OF NEUROCHEMISTRY, 2010, 112 (06) : 1552 - 1561
  • [50] BACE1, the Alzheimer’s beta-secretase enzyme, in health and disease
    Robert Vassar
    Molecular Neurodegeneration, 8 (Suppl 1)